Video

Todd Villines: Learning the Latest in Anticoagulants

Author(s):

Since the days when Warfarin was the lone option in anticoagulants a considerable amount of research has been conducted leading to the development of new novel oral anticoagulants.

Since the days when Warfarin was the lone option in anticoagulants a considerable amount of research has been conducted leading to the development of new novel oral anticoagulants.

Early in his career at Walter Reed National Military Medical Center Lt. Col. Todd C. Villines, MD, who considers himself a "preventative cardiologist," was named anticoagulation clinic director at the facility. Since that time he said he has seen the field grow and change dramatically to give patients more effective options without many of the safety concerns. The newer medications, some approved 6 years ago have shown what he called a "step forward," in helping patients who were otherwise undertreated. While discussing how the medications can help reduce stroke in many patients Villines said he was glad to see the progress made during the annual meeting of the American College of Cardiology in Chicago.

Related Videos
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
Orly Vardeny, PharmD | Credit: JACC Journals
© 2024 MJH Life Sciences

All rights reserved.